The journal Nature identifies seven transformative technologies for 2025, with self-driving laboratories and advanced immunotherapies set to accelerate …
The journal Nature identifies seven transformative technologies for 2025, with self-driving laboratories and advanced immunotherapies set to accelerate …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
Arrowhead Pharmaceuticals’ NDA for plozasiran in rare, life-threatening FCS wins FDA acceptance, setting a PDUFA action date and …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …
Avance Clinical solidifies its position as the leading early‑phase CRO in Australia—backed by rapid trial starts and generous …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Mereo BioPharma’s Phase 3 study in osteogenesis imperfecta progresses to interim analysis, while alvelestat gains momentum toward EU orphan …
Bio‑Path outlines a robust development and regulatory path ahead, aiming to advance both cancer and obesity-focused therapies using …